Search | Clinical Trials Finder

Conditions: Delirium
Interventions: Guanfacine, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Esophagitis, Reflux, Esophagitis, Peptic
Interventions: Dexlansoprazole MR, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 80
States / cities: Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more

Conditions: Healthy Volunteers
Interventions: IW-3300, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gastric Motility Disorder
Interventions: Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Estriol, Placebo, Copaxone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Acromegaly
Interventions: Paltusotine, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Columbus, Ohio • Dallas, Texas

Conditions: Chronic Hepatitis C
Interventions: BMS-650032 or Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Cypress, California • Orlando, Florida • Baltimore, Maryland + 2 more

Conditions: Long Covid
Interventions: tenofovir disoproxil/emtricitabine, Selzentry, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastroesophageal Reflux Disease, Erosive Esophagitis
Interventions: Dexlansoprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 32
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more

Conditions: Hidradenitis Suppurativa
Interventions: Brensocatib, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more

Conditions: Diabetes, Atherosclerosis
Interventions: sitagliptin, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Pregnancy Induced Hypertension, Preeclampsia and Eclampsia, Gestational Hypertension
Interventions: L-citrulline, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Alzheimer Disease, Dementia, Alzheimer Type
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 21
States / cities: Bellflower, California • Costa Mesa, California • Glendale, California + 18 more

Conditions: Knee Osteoarthritis, Cartilage Degeneration
Interventions: Teriparatide, Placebo; Drug
Lead sponsor: Christopher Ritchlin; Other
Eligibility: 40 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Tinea Pedis, Athlete's Foot
Interventions: Econazole Nitrate Foam 1%, Vehicle Foam; Drug · Other
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more

Conditions: Depression
Interventions: EVT 101, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Oceanside, California • San Diego, California • Tampa, Florida + 11 more

Conditions: Opioid Use Disorder, Opioid Dependence
Interventions: Drug A (Blinded Drug), Drug B (Blinded Drug), Drug C (Blinded Drug), Drug D (Blinded Drug), Suvorexant (20mg/day), Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, Exenatide LAR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 7
States / cities: Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 84
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 45
States / cities: Phoenix, Arizona • Arcadia, California • Encino, California + 39 more

Conditions: Atrial Fibrillation
Interventions: dapagliflozin, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Portland, Maine • Detroit, Michigan • Rochester, New York

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: MEM 3454, Placebo for MEM 3454; Drug
Lead sponsor: Memory Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 44
States / cities: Lemon Grove, California • Newport Beach, California • Oceanside, California + 29 more

Conditions: Covid19
Interventions: Fluticasone, Placebo; Drug · Other
Lead sponsor: Susanna Naggie, MD; Other
Eligibility: 30 Years and older
Enrollment: 1,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 87
States / cities: Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more

Conditions: Hidradenitis Suppurativa
Interventions: Ritlecitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 30
States / cities: Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more

Search by objective public record fields.

The Effect of Guanfacine on Delirium in Critically Ill Patients

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Antiviral Clinical Trial for Long Covid-19

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy

Role of L-citrulline in Prevention of Pregnancy Associated Hypertension

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Teriparatide as a Chondroregenerative Therapy in OA

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Measuring Acute Drug Demand in Humans

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

Escitalopram in Adult Patients With Major Depressive Disorder

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.